Morphological Findings in Malignant Gliomas Before and After Interferon Therapy

  • G. Ebhardt
  • Th. Rommel
Conference paper
Part of the Advances in Neurosurgery book series (NEURO, volume 16)


Interferons represent a group of proteins and glycoproteins present in the body which — due to their antigenic, biological, and chemical properties — are divided into subgroups: alpha-interferon (IFN-α), beta-interferon (IFN-β), and gamma-interferon (IFN-γ). The various types of interferon differ in their biological range of effects, but they all show antiviral, immunomodulating, and antiproliferative activities. With the two last properties mentioned, therapeutic possibilities for tumors have become apparent. Up to now a great many results for interferon drugs in the treatment of tumors have been described: they range from the disappearance of the tumor to lack of response. Japanese teams have reported on initial, good clinical experience with interferon therapy in the case of malignant gliomas (11). In this study (12) it was shown that with malignant gliomas, therapy involving IFN-3 was superior to the other forms of interferon. In keeping with its strong linkage to serum protein, IFN-3 cannot pass the intact blood-brain barrier easily, with the result that the concentration in the fluid is low if there is intravenous injection. The therapeutically effective minimum concentration of IFN-β that is known from in vitro experiments is not achieved through systemic application (12).


Malignant Glioma Malignant Brain Tumor Interferon Therapy Glioblastoma Patient Effective Minimum Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alber FK (to be published) Erste Erfahrungen mit β-Interferon bei malignen Gliomen (systemische und intraläsionale Applikation)Google Scholar
  2. 2.
    Böker D-K (1982) Lymphocytic infiltration in human intracranial tumors — morphologic evidence for a host-immune reaction and comparison with the leukocyte migration inhibition (LMI test). Clin Neuro-pathol 1:113–120Google Scholar
  3. 3.
    Böker D-K, Kalff R, Gullotta F, Weekes-Scifert S, Möhrer U (1984) Mononuclear infiltrates in human intracranial tumors as a prognostic factor. Influence of preoperative steroid treatment I. Glioblastoma. Clin Neuropathol 3:143–147PubMedGoogle Scholar
  4. 4.
    Boëthius J, Blomgren H, Collins VP, Greitz T, Strander H (1983) The effect of systemic human interferon-alpha administration of patients with glioblastoma multiforme. Acta Neurochirurgica 68: 239–251PubMedCrossRefGoogle Scholar
  5. 5.
    Duff TA, Borden E, Bay J, Piepmeier J, Sielaff K (1986) Phase II trial of interferon-β for treatment of recurrent glioblastoma multiforme. J Neurosurg 64:408–413PubMedCrossRefGoogle Scholar
  6. 6.
    Heiß E Rios-Nogales L (1987) Interferon bei Glioblastomen? In: Symposium: Therapie primärer Hirntumoren. Essen, 26.–28.3., p 48Google Scholar
  7. 7.
    Jellinger K (1987) Pathology of human intracranial neoplasia. In: Jellinger K (ed) Therapy of malignant brain tumors. Springer, Wien New York, pp 1–90Google Scholar
  8. 8.
    Mahaley Jr. MS, Urso M, Whaley RA, Williams TE, Guaspari A (1984) Interferon as adjuvant therapy with initial radiotherapy of patients with anaplastic gliomas. J Neurosurg 61:1069–1071PubMedCrossRefGoogle Scholar
  9. 9.
    Mahaley Jr. MS (1985) Treatment of recurrent gliomas with interferon. In: Kirchner H, Schellekens H (eds) The biology of the interferon system. Elsevier, pp 529–533Google Scholar
  10. 10.
    Meier DH (1987) In-vitro sensitivity of primary brain tumors to interferon alpha, beta and gamma. In: Symposium: Therapie primärer Hirntumouren, Essen 26.–28.3., p 15Google Scholar
  11. 11.
    Nagai M, Arai T, Kohno S, Kohase M (1982) Interferon therapy for malignant brain tumors. In: Kono R, Vilcek J (eds) The clinical potential of interferons. University of Tokyo Press, Tokyo, pp 257–273Google Scholar
  12. 12.
    Nagai M, Arai T (1984) Treatment of malignant brain tumors with interferon. In: Kishida T (ed) Interferons. Jpn Convention Services, Osaka, pp 208–216Google Scholar
  13. 13.
    Otsuka S Handa H, Yamashita J, Suda K, Takeuchi J (1984) Single agent therapy of interferon for brain tumours: correlation between natural killer activity and clinical course. Acta Neurochirurgica 73:13–23PubMedCrossRefGoogle Scholar
  14. 14.
    Palma L, Di Lorenzo N, Guidetti B (1978) Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. J Neurosurg 49: 854–861PubMedCrossRefGoogle Scholar
  15. 15.
    Reincke M (1986) Die lymphozytäre Infiltration von astrocytären Tumoren, Oligodendrogliomen und oligo-astrocytären Mischgliomen. Inaugural-Dissertation, Universität KölnGoogle Scholar
  16. 16.
    Ridley A, Cavanagh JB (1971) Lymphocytic infiltration in glioma: evidence of possible host resistance. Brain 94:117–124PubMedCrossRefGoogle Scholar
  17. 17.
    Sieber B (1985) Lymphocytäre Infiltrationen im Glioblastom. Inaugural-Dissertation, Universität KölnGoogle Scholar
  18. 18.
    Stoltenburg-Didinger G, Cervós-Navarro J (1976) Ultrastruktur der Gefäße im Glioblastom. Deutsche Gesellschaft für Neuropathologie und Neuroanatomie, Jahrestagung, 8.–11.10., Berlin, p 44Google Scholar
  19. 19.
    Tanaka N, Nagao S, Tohgo A, Sekiguchi F, Kohno M, Ogawa H, Matsui T, Matsutani M (1983) Effects of human fibroblastic interferon on human gliomas transplanted into nude mice. Gann 74:308–316PubMedGoogle Scholar
  20. 20.
    Ueda S, Hirakawa K, Nakagawa Y, Suzuki K, Kishida T (1983) Brain tumors. In: Sikora K (ed) Interferon and cancer. New York, pp 129–139Google Scholar
  21. 21.
    Wüllenweber R, Kuhlendahl H, Miltz H (1973) Astrocytomas of the cerebral hemisperes. A review on 1500 cases. Proc German Society Neurosurg 3:100–107Google Scholar
  22. 22.
    Wüllenweber R, Kuhlendahl H, Miltz H, Grunert V, Sunder-Plassmann M (1973) Astrocytomas and glioblastomas: a comparative review of 2500 cases. Excerpta Medica 293:36–37Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • G. Ebhardt
    • 1
  • Th. Rommel
    • 1
  1. 1.Pathologisches Institut, Sektion NeuropathologieKrankenhaus MerheimKöln 91Germany

Personalised recommendations